The Albert L. Tucker and Elizabeth T. Tucker Postdoctoral Fellowship Established at the GW Cancer Center

The recently established GW Cancer Center is pleased to announce that the Albert L. Tucker and Elizabeth T. Tucker Postdoctoral Fellowship has been established by The Albert L. Tucker and Elizabeth T. Tucker Foundation in an amount of $1 million. The annual proceeds will be applied each year to support the postdoctoral training of a particularly promising young cancer researcher.

“We are very grateful for the support that has been provided by Tucker Foundation. It will enable us to provide valuable training to a fellow who will make a difference in the field of cancer research. We know that through gifts like this one, that GW Cancer Center will foster innovation and discovery in cancer research and clinical care," said Eduardo M. Sotomayor, M.D., Director of the GW Cancer Center.

The Albert L. Tucker and Elizabeth T. Tucker Foundation was established in 1995 and provides financial support primarily to hospitals and medical centers and other organizations providing health services, including hospices and nursing homes.

“The Tucker Foundation has provided funding for similar positions in the healthcare community in Washington, D.C., and has watched with great pride the achievements of the young medical scientists who have been sponsored through the generosity and foresight of the Foundation's two founders - Albert and Elizabeth Tucker," said Nicholas S. McConnell, President of The Albert L. Tucker and Elizabeth T. Tucker Foundation.

Latest News

What do you get when you combine a love of psychology with a keen interest in medicine? Clinical social worker Jessica Gelfarb knows that answer well. With one foot in both worlds, she helps GW Cancer Center patients navigate their most challenging life journeys. While she guides them through the…
Robert H. Miller’s appointment as interim vice provost for research will further build on progress led by Pamela M. Norris
Vishal Patel, MD, FAAD, FACMS, highlights the evolving role of PD-1 inhibitors in the management of nonmelanoma skin cancers.